Advertisement
Screener

PULMATRIX, INC. (PULM) Increase (Decrease) in Deferred Revenue

2.8 / 5 stars · 68/120 Roast Me

PULMATRIX, INC. Increase (Decrease) in Deferred Revenue

PULMATRIX, INC. (PULM) reported Increase (Decrease) in Deferred Revenue of -$4.34 million for the 12-month period ending 2024-12-31, per its S-4/A filed 2026-09-17.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInDeferredRevenue · last filed 2026-09-17

  • PULMATRIX, INC. increase (decrease) in deferred revenue for the quarter ending 2024-12-31 was $0.00.
  • PULMATRIX, INC. increase (decrease) in deferred revenue for the quarter ending 2024-09-30 was -$270.00K.
  • PULMATRIX, INC. increase (decrease) in deferred revenue for the quarter ending 2024-06-30 was -$93.00K.
  • PULMATRIX, INC. increase (decrease) in deferred revenue for the quarter ending 2024-03-31 was -$3.98M.
  • PULMATRIX, INC. increase (decrease) in deferred revenue for fiscal 2023 was -$1.82M.
  • PULMATRIX, INC. increase (decrease) in deferred revenue for fiscal 2022 was -$847.00K.
  • PULMATRIX, INC. increase (decrease) in deferred revenue for fiscal 2021 was -$3.33M.
  • PULMATRIX, INC. increase (decrease) in deferred revenue for fiscal 2020 was -$10.96M, a 151.46% decline from fiscal 2019.
Period endIncrease (Decrease) in Deferred Revenue 3 monthIncrease (Decrease) in Deferred Revenue 6 monthIncrease (Decrease) in Deferred Revenue 9 monthIncrease (Decrease) in Deferred Revenue 12 month
2024-12-31$0.00
derived: S-4/A 12 month − 10-Q 9 month · filed 2026-09-17
-$270.00K
derived: sum of 2 quarters · filed 2026-09-17
-$363.00K
derived: sum of 3 quarters · filed 2026-09-17
-$4.34M
S-4/A · filed 2026-09-17
2024-09-30-$270.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-16
-$363.00K
derived: sum of 2 quarters · filed 2025-10-16
-$4.34M
10-Q · filed 2025-10-16
-$5.03M
derived: sum of 4 quarters · filed 2025-10-16
2024-06-30-$93.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06
-$4.08M
10-Q · filed 2025-08-06
-$4.76M
derived: sum of 3 quarters · filed 2025-08-06
-$5.19M
derived: sum of 4 quarters · filed 2025-08-06
2024-03-31-$3.98M
10-Q · filed 2025-05-15
-$4.66M
derived: sum of 2 quarters · filed 2025-05-15
-$5.09M
derived: sum of 3 quarters · filed 2025-05-15
-$5.67M
derived: sum of 4 quarters · filed 2025-05-15
2023-12-31-$681.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21
-$1.11M
derived: sum of 2 quarters · filed 2025-03-21
-$1.69M
derived: sum of 3 quarters · filed 2025-03-21
-$1.82M
10-K · filed 2025-03-21
2023-09-30-$430.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08
-$1.00M
derived: sum of 2 quarters · filed 2024-11-08
-$1.14M
10-Q · filed 2024-11-08
-$1.19M
derived: sum of 4 quarters · filed 2024-11-08
2023-06-30-$574.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13
-$705.00K
10-Q · filed 2024-08-13
-$764.00K
derived: sum of 3 quarters · filed 2024-08-13
-$1.46M
derived: sum of 4 quarters · filed 2024-08-13
2023-03-31-$131.00K
10-Q · filed 2024-05-10
-$190.00K
derived: sum of 2 quarters · filed 2024-05-10
-$889.00K
derived: sum of 3 quarters · filed 2024-05-10
-$1.23M
derived: sum of 4 quarters · filed 2024-05-10
2022-12-31-$59.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28
-$758.00K
derived: sum of 2 quarters · filed 2024-03-28
-$1.09M
derived: sum of 3 quarters · filed 2024-03-28
-$847.00K
10-K · filed 2024-03-28
2022-09-30-$699.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09
-$1.04M
derived: sum of 2 quarters · filed 2023-11-09
-$788.00K
10-Q · filed 2023-11-09
-$1.18M
derived: sum of 4 quarters · filed 2023-11-09
2022-06-30-$337.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10
-$89.00K
10-Q · filed 2023-08-10
-$478.00K
derived: sum of 3 quarters · filed 2023-08-10
-$1.54M
derived: sum of 4 quarters · filed 2023-08-10
2022-03-31$248.00K
10-Q · filed 2023-05-12
-$141.00K
derived: sum of 2 quarters · filed 2023-05-12
-$1.20M
derived: sum of 3 quarters · filed 2023-05-12
-$1.70M
derived: sum of 4 quarters · filed 2023-05-12
2021-12-31-$389.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30
-$1.45M
derived: sum of 2 quarters · filed 2023-03-30
-$1.95M
derived: sum of 3 quarters · filed 2023-03-30
-$3.33M
10-K · filed 2023-03-30
2021-09-30-$1.06M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10
-$1.56M
derived: sum of 2 quarters · filed 2022-11-10
-$2.94M
10-Q · filed 2022-11-10
-$4.85M
derived: sum of 4 quarters · filed 2022-11-10
2021-06-30-$496.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10
-$1.88M
10-Q · filed 2022-08-10
-$3.79M
derived: sum of 3 quarters · filed 2022-08-10
-$6.95M
derived: sum of 4 quarters · filed 2022-08-10
2021-03-31-$1.38M
10-Q · filed 2022-05-12
-$3.30M
derived: sum of 2 quarters · filed 2022-05-12
-$6.45M
derived: sum of 3 quarters · filed 2022-05-12
-$9.60M
derived: sum of 4 quarters · filed 2022-05-12
2020-12-31-$1.92M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29
-$5.07M
derived: sum of 2 quarters · filed 2022-03-29
-$8.22M
derived: sum of 3 quarters · filed 2022-03-29
-$10.96M
10-K · filed 2022-03-29
2020-09-30-$3.16M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10
-$6.30M
derived: sum of 2 quarters · filed 2021-11-10
-$9.04M
10-Q · filed 2021-11-10
-$3.52M
derived: sum of 4 quarters · filed 2021-11-10
2020-06-30-$3.15M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10
-$5.88M
10-Q · filed 2021-08-10
-$369.00K
derived: sum of 3 quarters · filed 2021-08-10
-$1.77M
derived: sum of 4 quarters · filed 2021-08-10
2020-03-31-$2.74M
10-Q · filed 2021-05-11
$2.78M
derived: sum of 2 quarters · filed 2021-05-11
$1.37M
derived: sum of 3 quarters · filed 2021-05-11
2019-12-31$5.51M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23
$4.11M
derived: sum of 2 quarters · filed 2021-03-23
$21.29M
10-K · filed 2021-03-23
2019-09-30-$1.41M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12
$15.78M
10-Q · filed 2020-11-12
2019-06-30$17.18M
10-Q · filed 2020-08-07

Similar stocks

Stock NameCountryMarket CapPE Ratio
Ernexa Therapeutics Inc. (ERNA)United States$0.006B
ProPhase Labs, Inc. (PRPH)United States$0.006B-0.06
Xenetic Biosciences, Inc. (XBIO)United States$0.006B
Enveric Biosciences, Inc. (ENVB)United States$0.007B-0.63
Bolt Biotherapeutics, Inc. (BOLT)United States$0.007B-0.26
SYNLOGIC, INC. (SYBX)United States$0.007B
Processa Pharmaceuticals, Inc. (PCSA)United States$0.005B
Acurx Pharmaceuticals, Inc. (ACXP)United States$0.007B-0.97
AMARIN CORP PLC\UK (AMRN)$0.005B-247.24
CNS Pharmaceuticals, Inc. (CNSP)United States$0.007B